TCM Biotech International Corp.   Report issue

For profit Phase 2 Phase 3
Founded: Taipei Taiwan (1998)

Organization Overview

First Clinical Trial
2007
NCT00556504
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

TCM Biotech International Corp.

Active Ingredients

Drugs in Phase 3 Trials (3)

interferon alpha-2b (Intron-A) (2 trials)

ribavirin (virazole) (2 trials)

tcm-700c (2 trials)

Drugs in Phase 2 Trials (1)

ptx-9908 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 2)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4